Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$14.65 USD
-0.14 (-0.95%)
Updated Oct 2, 2024 03:59 PM ET
After-Market: $14.61 -0.04 (-0.27%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.65 USD
-0.14 (-0.95%)
Updated Oct 2, 2024 03:59 PM ET
After-Market: $14.61 -0.04 (-0.27%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Zacks News
Assembly Biosciences (ASMB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.98% and 27.73%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Segmental Growth Aid Hologic (HOLX) in Q4 Earnings?
by Zacks Equity Research
Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
Developments in business segments are likely to have aided Thermo Fisher (TMO) in the third quarter.
Top Ranked Momentum Stocks to Buy for October 18th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 18th
Will Assembly Biosciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Assembly Biosciences.
Assembly Biosciences (ASMB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 34.55% and -20.97%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.87% and 1.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
by Zacks Equity Research
Continued price erosion and intensifying competition in generic drug market is negatively impacting the top line of industry participants. However, stabilizing outlook is encouraging.
Mylan (MYL) Jumps: Stock Rises 7.1%
by Zacks Equity Research
Mylan (MYL) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Amphastar Pharmaceuticals (AMPH) Catches Eye: Stock Jumps 6.7%
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Assembly Biosciences (ASMB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.71% and 33.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in Assembly Biosciences (ASMB) Stock
by Zacks Equity Research
Assembly Biosciences (ASMB) needs investors to pay close attention to the stock based on moves in the options market lately.
Assembly Biosciences (ASMB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -44.44% and -2.49%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights: H&E Equipment Services, Nomad Foods, Strayer Education, BioLife Solutions and Assembly Biosciences
by Zacks Equity Research
Zacks.com featured highlights: H&E Equipment Services, Nomad Foods, Strayer Education, BioLife Solutions and Assembly Biosciences
New Analyst Coverage Puts the Spotlight on These 5 Stocks
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.
New Strong Sell Stocks for September 18th
by Zacks Equity Research
Here are 4 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for August 31st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for August 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Assembly Biosciences (ASMB) Looks Good: Stock Up 13.9%
by Zacks Equity Research
Assembly Biosciences, Inc. (ASMB) was a big mover last session, as the company saw its shares rise nearly 14% on the day.